Physician profile
Chong Cheever
NPI 1295063683
$886.63
in general payments reported to CMS, 2019-2025
11 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $412 · 2023: $176 · 2024: $97.09 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.20 |
| Education | $119.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $201.70 | 2021-2024 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $153.98 | 2022-2025 | |
| United Therapeutics Corporation | $137.78 | 2022-2023 | Tyvaso |
| Glaxosmithkline, LLC. | $113.34 | 2022-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $62.71 | 2021-2023 | Tezspire, Fasenra |
| Insmed, INC. | $57.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.12 | 2023 | |
| Mylan Specialty L.P. | $35.10 | 2023-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $32.81 | 2023 | |
| Advanced Respiratory, INC | $24.90 | 2021 | |
| Genzyme Corporation | $20.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chong Cheever listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.